The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 30, 2019

Filed:

Jul. 27, 2016
Applicant:

Pain Therapeutics, Inc., Austin, TX (US);

Inventors:

Hoau-Yan Wang, Philadelphia, PA (US);

Lindsay Burns Barbier, Austin, TX (US);

Assignee:

Pain Therapeutics, Austin, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/395 (2006.01); A61K 31/47 (2006.01); A61K 31/5375 (2006.01); A61K 31/40 (2006.01); A61K 31/426 (2006.01); A61K 31/435 (2006.01); A61K 31/445 (2006.01); A61K 31/472 (2006.01); A61K 31/4741 (2006.01); A61K 31/485 (2006.01); A61K 31/495 (2006.01); A61K 31/5377 (2006.01); A61K 31/54 (2006.01); A61K 31/551 (2006.01); A61K 31/625 (2006.01); A61K 31/438 (2006.01); A61K 31/444 (2006.01);
U.S. Cl.
CPC ...
A61K 31/395 (2013.01); A61K 31/40 (2013.01); A61K 31/426 (2013.01); A61K 31/435 (2013.01); A61K 31/438 (2013.01); A61K 31/444 (2013.01); A61K 31/445 (2013.01); A61K 31/47 (2013.01); A61K 31/472 (2013.01); A61K 31/4741 (2013.01); A61K 31/485 (2013.01); A61K 31/495 (2013.01); A61K 31/5375 (2013.01); A61K 31/5377 (2013.01); A61K 31/54 (2013.01); A61K 31/551 (2013.01); A61K 31/625 (2013.01);
Abstract

A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 μM concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS.-


Find Patent Forward Citations

Loading…